But, this new drug on the block really isnt so new
Schwarzer, G., Carpenter, J
Systemic dyslipidemia in age-related macular degeneration: an updated systematic review and meta-analysis
So these are interesting areas that I definitely, um, like want to keep tracking because I think that if we can prevent neurodegenerative disease, then we need to start having a conversation in women's health if this is a tool to do that
This scheduling constraint is one reason Novo Nordisk can't simply "make more Wegovy" by reallocating Ozempic production capacity without 6-8 weeks of transition time
Vision loss A July 3, 2024 study first linked Ozempic and Wegovy use to an increased risk of vision loss in diabetic or overweight patients